News | October 28, 2021
Indian Pharma Market witnesses rise in volumes and prices in September.
Acute therapies continue to report strong growth compared to chronic ones.
Acute therapies continue to report strong growth compared to chronic ones.
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
